Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene

Table 2 Baseline characteristics

Characteristic	Treated patients with HAE-PLG N = 59*
Sex, n (%)
Male	17 (28.8)
Female	42 (71.2)
Age, year	53.7 ± 17.1
Mean disease duration, year	21.4 ± 15.3
Laboratory parameters
C1-INH activity (%) (RR 70–130)	99.4 ± 17.3
C1-INH protein (mg/dL) (RR 15.4–33.8)	24.8 ± 5.6
C4 (mg/dL) (RR 16.4–31.3)	24.0 ± 8.2
Plasminogen activity (%)	91 ± 17.4**

C1-INH C1 inhibitor, HAE hereditary angioedema, HAE-PLG HAE with the c.988A > G (p.K330E) variant in the PLG gene; N number of patients, n number of patients in the specified category, RR reference range, ± standard deviation
*Patients who had received treatment for acute attacks and/or long-term prophylaxis
**in 34 patients only; control group see text

ISSN: 1750-1172